Table 3.
Summary of clinical outcomes (n = 90)
| Criteria / Intervention | Number of Patients (n) | Percentage (%) |
|---|---|---|
| Persistence of Rubeosis Iridis | ||
| • At 1st week | 40 | 44.4% |
| • At 1st month | 33 | 36.7% |
| • At 3rd month | 20 | 28.5% |
| Treatments Applied | ||
| • Intracameral + intravitreal bevacizumab (initial; all patients) | 90 | 100% |
| • Trabeculectomy with mitomycin C (for patients with persistent rubeosis/high IOP & vision potential) | 10 | 11.1% |
| • CCT (for blind and painful eyes) | 11 | 12.2% |
| • PRP | 60 | 66.7% |
| • Second dose of combined bevacizumab (for persistent rubeosis at 1 month) | 13 | 14.4% |
| • Ongoing intravitreal bevacizumab treatments | 52 | 57.8% |
| Complications | ||
| • Hyphema (after intracameral + intravitreal bevacizumab) | 3 | 3.3% |
| • Persistent pain (refused CCT) | 4 | 4.4% |
CCT: Cyclocryotherapy; IOP: Intraocular pressure; PRP: Panretinal photocoagulation